4D Molecular Therapeutics, Inc.
FDMTNASDAQHealthcare● Active
$8.64
+$0.00(+0.00%)
Market Cap$451666835
P/E Ratio—
52W High$12.34
52W Low$3.68
4D Molecular Therapeutics, Inc. (FDMT) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · FDMT · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($140.11M) | ($160.87M) | ($100.84M) | ($107.49M) | ($71.32M) |
| Depreciation & Amort. | $7.63M | $6.71M | $5.75M | $3.88M | $3.02M |
| Stock-Based Comp. | $22.02M | $26.12M | $19.66M | $17.12M | $13.80M |
| Change in Working Capital | $6.17M | $0.54M | $0.63M | ($1.34M) | ($15.53M) |
| Net Cash from Operations | ($109.08M) | ($134.59M) | ($75.79M) | ($86.69M) | ($69.13M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.54M) | ($3.79M) | ($2.77M) | ($11.54M) | ($9.11M) |
| Purchases of Investments | ($442.82M) | ($467.65M) | ($54.80M) | ($153.31M) | ($168.57M) |
| Sales of Investments | $350.38M | $169.00M | $0.00M | $147.80M | $5.00M |
| Net Cash from Investing | ($92.97M) | ($302.44M) | $115.72M | ($17.05M) | ($172.68M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Financing | $112.96M | $337.25M | $156.83M | $3.08M | $118.09M |
| Free Cash Flow | |||||
| Free Cash Flow | ($109.08M) | ($138.37M) | ($78.56M) | ($98.22M) | ($78.24M) |
| FCF Margin %(computed) | -128.02% | — | -379.11% | — | -433.77% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more 4D Molecular Therapeutics, Inc. data
About 4D Molecular Therapeutics, Inc. (FDMT) Cash Flow Statement
4D Molecular Therapeutics, Inc. generated operating cash flow of ($0.11B) and free cash flow of ($0.11B) for 2025 — a FCF margin of -128.02%. Capital expenditure was ($0.00B).
Frequently asked questions
FDMT · 4 questions4D Molecular Therapeutics, Inc. generated free cash flow of ($0.11B) for 2025, up 21.2% year-over-year.
FDMT free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10